Posted by Michael Wonder on 04 Dec 2024
Valneva submits label extension application for its Chikungunya vaccine, Ixchiq, to the US FDA
26 November 2024 - To potentially include adolescents and antibody persistence up to two years.
Valneva today announced that it has submitted a label extension application to the US FDA to potentially extend the use of its chikungunya vaccine Ixchiq, which is currently approved in adults, to adolescents aged 12 to 17 years.
